2001; Brunswick et al. 2002]. Moreover, the brain concentration of fluoxetine and its metabolites keep on increasing through at least the first 5 weeks of treatment [Henry et al. 2005]. This means that the full benefits of the current dose received by a patient are not realized for at least a month after initiation. For example, in one 6-week study, the median time for achieving Inhibitors,research,lifescience,medical consistent response was
29 days [Perez et al. 2001]. Likewise, complete excretion of the drug may also take several weeks. During the first week after treatment discontinuation, the brain concentration of fluoxetine decreases by only 50% [Guze and Gitlin, 1994], the blood level of norfluoxetine after 4 weeks following treatment discontinuation is about 80% of the level registered by the end of the first treatment week, and norfluoxetine was still detectable in blood after Inhibitors,research,lifescience,medical 7 weeks after the discontinuation [Perez et al. 2001]. This extended half-life appears to protect against sporadic noncompliances [Guze and Gitlin, 1994] and against the occurrence of several withdrawal phenomenon
of fluoxetine over other SSRIs. However, in the P450 inhibitor datasheet context of this discussion, the long half-life of fluoxetine and its desmethyl metabolite may account for such late onset hyperprolactinemia and resulted in prolonged recovery time after Inhibitors,research,lifescience,medical fluoxetine discontinuation in all of these patients. The prominence of clinical implications of inter-individual variability and the possibility of impact of genetic polymorphism cannot be ruled out in this context. However, we are not aware of any study conducted to date addressing these relevant Inhibitors,research,lifescience,medical issues. By considering all of these aspects of discussion an attempt was made to depict putative mechanism of increasing prolactin level by fluoxetine (Figure 1). The exact insight of increased risk for neuroendocrine abnormalities is uncertain, but their prevalence must be correlated as the classic pathological manifestations of hyperprolactinemia are galactorrhea, amenorrhea, infertility, and decreased libido in women, and erectile dysfunction, hypogonadism, and infertility in males. The long-term
clinical sequelae of hyperprolactinemia are obscure Inhibitors,research,lifescience,medical and can lead to Tolmetin deleterious chronic pathological conditions such as osteopenia both in men and women, and the possibility of increased risk of breast cancer in women. Association of prolactin levels with impaired fertility, decreased bone density, and breast cancer are yet to be established. The likelihood of developing these perilous neuroendocrinological complications should also be an important consideration as these unpredictable conditions might pose a major public negative health impact [Segal et al. 1979; Seppala, 1978; Gomez et al. 1977; Carter et al. 1978]. The growing number of individual case reports could be signifying a strong association of SSRIs with prolactin abnormalities. Therefore, knowledge of their effect on prolactin homeostasis is extremely important.
No related posts.